9/10/2008 8:55:20 AM
MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor) today announced that it has entered into an agreement with Massachusetts General Hospital (MGH) for exclusive, worldwide rights to develop and commercialize T-cell receptors (TCRs) specific for cells infected by HIV and Hepatitis C Virus (HCV). The license has resulted from the success of Altor’s collaboration established in 2004 with Howard Hughes Medical Institute and the Partners AIDS Research Center at MGH. Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor (STAR™) technology.
comments powered by